Unlocking the Power of miRNA Biomarker Discovery with NGS and dPCR
The evolution of next-generation sequencing (NGS) technologies has revolutionized the field of gene expression analysis, making it possible to discover and validate biomarkers with unprecedented precision. In particular, NGS has enhanced our ability to profile miRNAs, small RNAs, and splice variants, offering insights into complex biological processes and disease mechanisms. These advancements are especially crucial for challenging sample types such as liquid biopsies, FFPE (formalin-fixed, paraffin-embedded) tumor samples, and exosomes.
The Role of miRNAs in Disease Biomarkers
MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a key role in regulating gene expression. Dysregulated miRNAs are often associated with various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. As such, miRNAs have emerged as promising biomarkers for diagnosis, prognosis, and therapeutic response. However, to harness the full potential of miRNAs, researchers must navigate the complexities of their discovery and verification.
Comprehensive Workflow for miRNA Biomarker Discovery
The process of miRNA biomarker discovery involves several key steps:
- Sample Extraction & Library Preparation: Successful miRNA-seq begins with high-quality RNA extraction, especially from challenging sample types. The preparation of libraries is crucial for ensuring accurate sequencing results, allowing for the detection of low-abundance miRNAs.
- Data Analysis with Bioinformatics Pipelines: Once sequencing data is obtained, bioinformatics tools are employed to map, quantify, and analyze miRNAs. This step is critical for identifying potential biomarkers, splice variants, and isoforms, which are essential for understanding disease mechanisms.
- dPCR Assay Design: After identifying miRNA biomarkers, digital PCR (dPCR) plays a crucial role in validating these biomarkers with high sensitivity and specificity. By designing dPCR assays based on sequencing data, researchers can ensure robust biomarker detection and quantification in clinical applications.
Best Practices for NGS Projects
To ensure the success of miRNA-seq projects, it’s essential to follow best practices. These include optimizing sample quality, collaborating with sequencing cores for expert advice, and maintaining a structured workflow for bioinformatics analysis.
Join Dr. Samuel Rulli for In-Depth Insights
In our upcoming webinar, Dr. Samuel Rulli, Director of Global Product Management at QIAGEN, will guide you through a comprehensive workflow for miRNA biomarker discovery and verification using NGS and dPCR. Dr. Rulli, a recognized expert in RNA-seq profiling, will provide actionable insights on miRNA-seq success, data analysis, and assay design to help researchers and clinicians uncover valuable disease biomarkers.
Webinar Details:
- Speaker: Dr. Samuel Rulli, Ph.D.
- Host: QIAGEN
- Topics Covered:
- miRNA-seq sample extraction and library prep
- Bioinformatics pipeline for miRNA analysis
- Design and validation of miRNA biomarkers using dPCR
- Best practices for working with sequencing cores
Whether you’re new to miRNA research or looking to optimize your sequencing workflow, this session will equip you with the knowledge to advance your biomarker discovery projects. Don’t miss this opportunity to learn from one of the leaders in the field!
Feel free to adjust the post content depending on your audience or platform!
